Aytu BioPharma, Inc. — Form 10-Q Summary
Reporting period: The filing covers the three months ended September 30, 2021 (the company’s fiscal first quarter of 2022), compared with the three months ended September 30, 2020. The request metadata’s “2021 Q1” does not match the period stated in the filing.
Financial results
| Metric | Quarter ended Sep. 30, 2021 | Quarter ended Sep. 30, 2020 |
|---|---|---|
| Net product revenue | $21.9 million | $13.5 million |
| Gross profit | $12.5 million | $9.5 million |
| Gross margin | 56.9% | 70.0% |
| Operating loss | $27.7 million | $3.6 million |
| Net loss | $27.9 million | $4.3 million |
| Cash used in operating activities | $3.8 million | $8.0 million |
- Revenue rose 62%, primarily reflecting Neos Therapeutics’ ADHD products, acquired in March 2021, and higher Consumer Health revenue. Consumer Health revenue was $8.0 million versus $7.8 million; Aytu BioPharma segment revenue was $13.9 million versus $5.8 million.
- Gross profit increased, but cost of sales grew faster than revenue; gross margin fell about 13 percentage points. The filing attributes higher costs in part to Neos product manufacturing and related depreciation and amortization.
- Operating expenses included a $19.5 million goodwill impairment charge. Excluding this unusual charge, the reported loss still reflects higher R&D, selling and marketing, and general and administrative costs.
- Cash, cash equivalents and restricted cash totaled $40.6 million at September 30, down from $49.9 million at June 30. Total assets were $227.7 million and stockholders’ equity was $111.5 million.
- Current assets of $89.0 million were below current liabilities of $98.0 million. The balance sheet reported $16.5 million of current debt and a separate $4.5 million short-term line-of-credit balance. The Deerfield facility, including its exit fee, was due May 11, 2022; the Encina revolving facility also matured May 11, 2022.
Material changes and notable items
- The $19.5 million goodwill impairment followed a continuing decline in the company’s share price and a higher risk-adjusted discount rate in the valuation. The impairment applied to the Aytu BioPharma segment; the Consumer Health segment was not impaired.
- Neos’ inclusion drove much of the year-over-year increase in revenue and operating costs. Aytu also acquired rights to AR101, an investigational candidate for vascular Ehlers-Danlos syndrome, with potential earn-out payments of up to $67.5 million, generally payable in cash or shares at the company’s option.
- Aytu agreed to transfer MiOXSYS assets to UAB Caerus Biotechnologies for approximately $0.5 million plus royalties of 5% of global net revenue for five years. The filing says $0.1 million received was deferred pending satisfaction of agreement conditions.
- The company discontinued Adzenys ER as of September 30, 2021. It also reported a $0.2 million inventory write-down.
Liquidity, outlook and risks
- Management stated that cash on hand and expected product-sale proceeds were expected to fund operations for the 12 months following the filing date, and reported no substantial doubt about the company’s ability to continue as a going concern. However, operations have historically consumed cash and management said it may need to reduce expenses, renegotiate debt, or raise additional capital. There is no assurance capital will be available on acceptable terms.
- Management expected operating costs to increase as it integrated Neos, invested in product development, pursued sales growth and considered acquisitions. The filing provides no quantified earnings or revenue guidance.
- Key risks include COVID-19-related disruption, possible employee attrition associated with a proposed vaccination-or-testing rule, dependence on additional financing, debt repayment and covenant obligations, and significant acquisition-related commitments. The company disclosed opioid-related lawsuits involving Neos and stated it could not predict their financial impact.
- Management said disclosure controls were effective and that a previously identified material weakness concerning goodwill, intangible assets and long-lived asset impairment accounting had been remediated through enhanced controls and third-party review. The company noted there can be no assurance future weaknesses will be avoided.
Investor verification priorities
- Confirm the correct reporting period: the filed quarter is ended September 30, 2021, not calendar-year Q1 2021.
- Review the assumptions behind the $19.5 million goodwill impairment and monitor for further impairment or valuation changes.
- Assess liquidity against the May 2022 debt maturities, current-liability deficit, cash burn and availability and potential dilution from equity financing.
- Track whether revenue growth from Neos products can improve gross margin and offset higher operating expenses.
- Review the terms, timing and potential scale of contingent consideration, fixed payments, AR101 milestones and other contractual commitments.